ADXS News and Press, Advaxis From 11/24/20

PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offerin...

Advaxis (ADXS) -14.2% AH, seeks to offer and sell shares and warrants to purchase shares in an underwritten public offering.Underwriters granted a 30-day option to purchase up to an additional 15% of the shares.Size, terms of the offering have not yet been disclosed.Proceeds to...

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it intends to offer and sell shares of i...

Are These On Your List Of Penny Stocks To Watch Right Now? What are penny stocks ? Based on the standard definition, penny stocks are shares of companies trading below $5. This simple definition gives a lot to be desired if you’re brand new to trading. Most people looking to ...

Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA ® Biomarker data confirms on-mechanism activation of innate and adaptive immune responses to ADXS-503 AD...

Are These Biotech Penny Stocks On Your Watch List Right Now? Whether you’re trading penny stocks or blue chips , the goal is the same: make money and repeat. However, with a potentially new President coming into office, there could be a few things to monitor right now. Fi...

3 Penny Stocks To Watch To Start The Week Penny stocks are once again at the center of attention on Monday. These low priced shares are some of the most aggressive, high-risk investments anyone can make. But with the right strategy and risk tolerance, you can consistently make mon...

Advaxis (ADXS) announces updated clinical results from the combination arm of its Phase 1/2 study evaluating ADXS-503 in combination with Merck's (MRK) KEYTRUDA (pembrolizumab), an anti-PD-1 therapy in non-small cell lung cancer ((NSCLC)).ADXS-503 is the first drug construct from the Com...

Disease control rate of 67% in first six evaluable patients who had progressed on KEYTRUDA Approximate 50% improvement in disease control rate versus the rate s reported in other checkpoint rechallenge studies Durable, sustained tumor ...

Are These On Your List Of Penny Stocks To Buy Or Avoid Right Now? Making a list of penny stocks right now? Whether you’re looking for tech penny stocks to buy, biotech stocks to watch, or other industry names, these cheap stocks are seeing explosive momentum this ...